ÂÜÀòÂÒÂ×

The Research and Development team at HilleVax spearheads the creation and refinement of novel vaccines, including the HIL-214 candidate aimed at preventing norovirus-induced gastroenteritis. The team is composed of experts in various disciplines such as preclinical development, manufacturing sciences, clinical serology assay development, and immunology. Their collaborative efforts ensure the rigorous evaluation and advancement of vaccine candidates from early research stages through to clinical trials.